MTOR and cancer: The capacity that lncRNAs have shown to restore sensitivity to standard chemotherapy constitutes an attractive strategy for overcoming resistance during cancer treatments in the future because lncRNA-involving approaches could be used in those patients that evidence resistance to conventional drugs or could eventually develop resistance to chemical inhibitors and/or specific antibodies of the PI3K/AKT/mTOR axis.